PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

被引：0
|
作者：
Robert D. Morgan
Andrew R. Clamp
D. Gareth R. Evans
Richard J. Edmondson
Gordon C. Jayson
机构：
[1] The Christie NHS Foundation Trust,Department of Medical Oncology
[2] The University of Manchester,Manchester Cancer Research Centre
[3] University of Manchester,Division of Evolution and Genomic Sciences, Manchester Academic Health Science Centre
[4] Central Manchester NHS Foundation Trust,Department of Obstetrics and Gynaecology, St Mary’s Hospital
[5] University of Manchester,Division of Cancer Sciences, Faculty of Biology, Medicine and Health
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
Ovarian cancer; Platinum sensitivity; PARP inhibitors; BRCA mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：647 / 658
页数：11
相关论文
共 50 条
  • [1] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Morgan, Robert D.
    Clamp, Andrew R.
    Evans, D. Gareth R.
    Edmondson, Richard J.
    Jayson, Gordon C.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 647 - 658
  • [2] Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
    Abdallah, Reem
    Atallah, David
    Bitar, Nizar
    Chahine, Georges
    Ghanem, Hady
    Ghosn, Marwan
    Kattan, Joseph
    Nasr, Fadi
    Makdessi, Joseph
    Shamseddine, Ali
    [J]. GYNECOLOGIC ONCOLOGY REPORTS, 2023, 47
  • [3] Genetic variation in platinum-sensitive and platinum-resistant high-grade serous epithelial ovarian cancer
    Castellano, Tara
    Clark, Leslie H.
    Rashid, Naim
    Bae-Jump, Victoria
    [J]. CANCER RESEARCH, 2017, 77
  • [4] Metabolism of Estrogens: Turnover Differs between Platinum-Sensitive and -Resistant High-Grade Serous Ovarian Cancer Cells
    Poschner, Stefan
    Wackerlig, Judith
    Castillo-Tong, Dan Cacsire
    Wolf, Andrea
    von der Decken, Isabel
    Rizner, Tea Lanisnik
    Pavlic, Renata
    Meshcheryakova, Anastasia
    Fritzer-Szekeres, Monika
    Mechtcheriakova, Diana
    Thalhammer, Theresia
    Jaeger, Walter
    [J]. CANCERS, 2020, 12 (02)
  • [5] Comprehensive genomic characterization of a large cohort of platinum-sensitive, high-grade serous ovarian cancer (HGSOC) FFPE specimens
    Haynes, Brian C.
    Fahey, Marie E.
    Myers, Darcy
    Ilsley, Diane
    Latham, Gary J.
    Somers, Elizabeth B.
    Nicolaides, Nicholas C.
    Schweizer, Charles
    O'Shannessy, Daniel J.
    [J]. CANCER RESEARCH, 2017, 77
  • [6] Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients
    Moya-Alarcon, Carlota
    Piera, Guiomar
    Callejo, Angel
    Gasco, Amaya
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (01) : 13 - 27
  • [7] The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
    Lorusso, Domenica
    Fontanella, Caterina
    Maltese, Giuseppa
    Lepori, Stefano
    Tripodi, Elisa
    Bogani, Giorgio
    Raspagliesi, Francesco
    [J]. EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 687 - 696
  • [8] Treatment strategy for patients with platinum-sensitive ovarian cancer using PARP inhibitors
    Matsumoto, Koji
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [9] Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L.
    Brenton, James D.
    [J]. LANCET ONCOLOGY, 2011, 12 (12): : 1169 - 1174
  • [10] PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
    Dickson, Kristie-Ann
    Xie, Tao
    Evenhuis, Christian
    Ma, Yue
    Marsh, Deborah J.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
12345